These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial. Heinzerling JH, Mileham KF, Robinson MM, Symanowski JT, Induru RR, Brouse GM, Corso CD, Prabhu RS, Haggstrom DE, Moeller BJ, Bobo WE, Fasola CE, Thakkar VV, Pal SE, Gregory JM, Norek SL, Begic XJ, Kesarwala AH, Burri SH, Simone CB. Lancet Oncol; 2024 Nov 27. PubMed ID: 39615497 [Abstract] [Full Text] [Related]
5. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences. Pillay J, Gaudet LA, Saba S, Vandermeer B, Ashiq AR, Wingert A, Hartling L. Syst Rev; 2024 Nov 26; 13(1):289. PubMed ID: 39593159 [Abstract] [Full Text] [Related]
6. Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial. Askanase AD, D'Cruz D, Kalunian K, Merrill JT, Navarra SV, Cahuzac C, Cornelisse P, Murphy MJ, Strasser DS, Trokan L, Berkani O. Lancet Rheumatol; 2024 Nov 22. PubMed ID: 39586304 [Abstract] [Full Text] [Related]
7. Tamoxifen for adults with hepatocellular carcinoma. Naing C, Ni H, Aung HH. Cochrane Database Syst Rev; 2024 Aug 12; 8(8):CD014869. PubMed ID: 39132750 [Abstract] [Full Text] [Related]
8. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone. Lee CC, Chen CW, Yen HK, Lin YP, Lai CY, Wang JL, Groot OQ, Janssen SJ, Schwab JH, Hsu FM, Lin WH. Clin Orthop Relat Res; 2024 Dec 01; 482(12):2193-2208. PubMed ID: 39051924 [Abstract] [Full Text] [Related]
9. A multicomponent psychosocial intervention to reduce substance use by adolescents involved in the criminal justice system: the RISKIT-CJS RCT. Coulton S, Nizalova O, Pellatt-Higgins T, Stevens A, Hendrie N, Marchand C, Vass R, Deluca P, Drummond C, Ferguson J, Waller G, Newbury-Birch D. Public Health Res (Southampt); 2023 Mar 01; 11(3):1-77. PubMed ID: 37254608 [Abstract] [Full Text] [Related]
10. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs. Marson AG, Burnside G, Appleton R, Smith D, Leach JP, Sills G, Tudur-Smith C, Plumpton CO, Hughes DA, Williamson PR, Baker G, Balabanova S, Taylor C, Brown R, Hindley D, Howell S, Maguire M, Mohanraj R, Smith PE. Health Technol Assess; 2021 Dec 01; 25(75):1-134. PubMed ID: 34931602 [Abstract] [Full Text] [Related]
11. Comparison of cognitive behaviour therapy versus activity management, both delivered remotely, to treat paediatric chronic fatigue syndrome/myalgic encephalomyelitis: the UK FITNET-NHS RCT. Crawley E, Anderson E, Cochrane M, Shirkey BA, Parslow R, Hollingworth W, Mills N, Gaunt D, Treneman-Evans G, Rai M, Macleod J, Kessler D, Pitts K, Cooper S, Loades M, Annaw A, Stallard P, Knoop H, Van de Putte E, Nijhof S, Bleijenberg G, Metcalfe C. Health Technol Assess; 2024 Oct 01; 28(70):1-134. PubMed ID: 39485730 [Abstract] [Full Text] [Related]
12. De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial. Chen XC, Jiao DC, Qiao JH, Wang CZ, Sun XF, Lu ZD, Li LF, Zhang CJ, Yan M, Wei Y, Chen B, Feng YQ, Deng M, Ma MD, Plichta JK, He YW, Liu ZZ. Lancet Oncol; 2024 Nov 26. PubMed ID: 39612919 [Abstract] [Full Text] [Related]
18. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol. Attard G, Murphy L, Clarke NW, Sachdeva A, Jones C, Hoyle A, Cross W, Jones RJ, Parker CC, Gillessen S, Cook A, Brawley C, Gilson C, Rush H, Abdel-Aty H, Amos CL, Murphy C, Chowdhury S, Malik Z, Russell JM, Parkar N, Pugh C, Diaz-Montana C, Pezaro C, Grant W, Saxby H, Pedley I, O'Sullivan JM, Birtle A, Gale J, Srihari N, Thomas C, Tanguay J, Wagstaff J, Das P, Gray E, Alzouebi M, Parikh O, Robinson A, Montazeri AH, Wylie J, Zarkar A, Cathomas R, Brown MD, Jain Y, Dearnaley DP, Mason MD, Gilbert D, Langley RE, Millman R, Matheson D, Sydes MR, Brown LC, Parmar MKB, James ND, STAMPEDE investigators. Lancet Oncol; 2023 May 13; 24(5):443-456. PubMed ID: 37142371 [Abstract] [Full Text] [Related]